Parkinson disease dementia dramatically increases mortality rates, patient expenditures, hospitalization risk, and caregiver burden. Currently, predicting Parkinson disease dementia risk is difficult, particularly in an office-based setting, without extensive biomarker testing.
D espite being classically considered a movement disorder, Parkinson disease (PD) has many nonmotor complications. Whereas there has been considerable progress in treating motor symptoms, nonmotor features, such as dementia, remain debilitating and relatively unmitigated. Parkinson disease dementia (PDD) reduces functional status, quality of life, and survival, contributing significantly to caregiver burden and disability-adjusted life years lost. 1 Six times more prevalent in patients with PD than in the general population, 2 dementia is the primary cause for nursing home placement in PD. 3 Prospective studies have estimated that dementia prevalence is as high as 52% after 4 years of follow-up and 60% after 12 years, increasing with age and disease severity. 4 Identifying individuals at high risk of dementia would facilitate therapeutic decisions and life planning for patients and improve cohort selection for randomized clinical trials. Numerous types of predictors of PDD have been discovered, including clinical, biological, neuropsychological, electrophysiological, or imaging-based predictors. Examples of well-documented predictors are age, 5 rapid eye movement sleep behavior disorder (RBD), [6] [7] [8] prodromal dementia symptoms (eg, hallucinations), GBA mutation status, 9 and cerebrospinal fluid (CSF) amyloid β 42 /tau ratio. 10 However, most of this
knowledge has yet to shape patient-care. Currently, prediction scores that integrate genetic and neuroimaging data are resource-intensive and so are difficult to apply to typical clinical settings. 11 To our knowledge, there is still no inexpensive and noninvasive tool that can predict dementia risk within a single office visit. For this purpose, we developed and tested a clinical scale, the Montreal Parkinson Risk of Dementia Scale (MoPaRDS), designed to be a rapid screening tool to predict the risk of dementia in PD.
Methods

MoPaRDS Scale Criteria
Based on a literature review and a 4.4-year prospective cohort study, we identified 8 simple clinical items (eTable 1 in the Supplement) that could be queried in a routine office setting. 7 These constituted the items of the MoPaRDS. There are 8 items, defined as: (1) 
Study Participants
We tested the predictive validity of the MoPaRDS in 4 cohorts: our original cohort, 7 2 others with established PD, and 1wi t hd en o v oP D( 
Outcome Assessment
The primary outcome was dementia status at last office visit. All participants were dementia-free at baseline according to the MDS level I criteria. On prospective follow-up, dementia was also defined by level I MDS criteria, namely global cognitive decline (Mini-Mental State Examination score <26) and impairment in more than 1 cognitive domain, resulting in substantial functional limitations to activities of daily living. 17 In
Key Points
Question How reliably can dementia be predicted in patients with Parkinson disease (PD) with a screening tool made up of clinical predictors?
Findings In this 4.4-year prospective study on 4 cohorts totaling 607 patients with PD, 70 had a diagnosis converted to dementia. The risk of developing PD dementia was 14-fold for a cutoff point of 4 or greater compared with a negative screen result, and the high-risk group had a 14.9% annual risk of dementia.
Meaning With simple measures that are assessable in a single office visit, this risk score rapidly and accurately screens for dementia risk in PD.
the original cohort, level II MDS criteria were applied as well because this definition boasts superior sensitivity while remaining comparably specific. 17 
Statistical Analysis
All patients were assessed for 8 baseline variables predictive of dementia that were identified in our 2 previous studies. 7, 8 Subsequently, the MoPaRDS was tallied for all patients. As a proof of concept, a survival analysis was run between participants scoring in the lowest tier (MoPaRDS, 0-3) and those scoring 4 and higher. Using the low-risk group as a reference, the hazard ratio for high-risk patients was calculated through a Cox regression.
To investigate weighting of the score items, participants were randomly split into a training set and a testing set for the purpose of cross-validation. Binary logistic regression analysis was performed on patients in the training set for each variable (eTable 2 in the Supplement) and the resulting odds ratios were proportionally reduced and rounded to integers, representing respective scale weights.
Both the unweighted and weighted models were compared in the testing set with receiver operating characteristic curves predicting final dementia status. Diagnostic accuracy for each cutoff point in the scales was then evaluated using coordinate points of the training set curve. On a second sensitivity analysis, this procedure was repeated on the testing set while excluding participants from the original cohort from whom the MoPaRDS items originated.
The association between the clinical scales and baseline markers of cognitive decline from multiple modalities was explored through bivariate correlations in the PPMI cohort. These included markers of Alzheimer pathology (CSF tau and Aβ 42 , obtained from T2 magnetic resonance imaging), and neuropsychological markers of limbic and posterior cortical functions, namely semantic fluency, Hopkins verbal learning test (memory) and Mayo Older Americans Normative Studies ageadjusted Benton judgment of line orientation test (visuoperceptual ability). 5, 18, 19 Analyses were performed with IBM SPSS, version 20.0 (IBM). Statistical significance was set at P = .05.
Results
All 8 variables were significantly associated with increased dementia risk over time (eTable 2 in the Supplement). After a mean (SD) follow-up of 4.4 (1.3) years (range 1-8 years), 70 of 607 patients (11.5%) developed dementia. Of the patients with de novo PD, the mean (SD) total MoPaRDS score was 1.8 (1.2), and 13 (3.3%) converted to dementia after 4.4 (1.0) years of follow-up. For the original cohort, mean (SD) MoPaRDS score was 3.5 (2.1) and 27 of 80 (34%) developed dementia during 4.4 (2.0) years of follow-up. In the other established PD cohorts, the baseline score (SD) was 3. Table 2 ). When limiting the cohort to patients without MCI (ie, maximum score = 7), average risk scores were notably lower. However, within each tertile, we noted no clear difference in dementia risk estimates compared with the entire cohort (eTable 3 in the Supplement).
Comparing participants who scored in the high-(6-8) and intermediate-risk group (4-5) on the MoPaRDS with the lowrisk group (0-3), the elevated risk groups developed dementia faster, with a hazard ratio of 20.8 (95% CI, 10.4-41.6) and 10.6 (95% CI, 5.1-19.8), respectively (P < .001) (Figure 1) .
Predictive validity of the MoPaRDS on the testing set, as measured by the area under the curve (AUC) of receiver operating characteristic curves, was 0.879 (95% CI, 0.816-0.942) (Figure 2) . Using the weighted MoPaRDS conferred no significant improvement in diagnostic accuracy, with an AUC of 0.885 (95% CI, 0.826-0.943). The optimal cutoff point for the unweighted scale, dictated by the upper leftmost point of the ROC for the training set, was 4 or greater and 13 or greater for the weighted score.
Across all cohorts, a positive screen result (≥4) yielded a sensitivity of 77.1% (95% CI, 65.6-86.3) and a specificity of 87.2% (95% CI, 84.0-89.9) (eTable 4 in the Supplement) for developing dementia over the 4-year follow-up. The positive predictive value was 43.9% (95% CI, 37.8-50.2) and the negative predictive value was 96.7% (95% CI, 95.0-97.9), influenced by the low prevalence of the primary outcome. The positive likelihood ratio was 5.94 (95% CI, 4.08-8.65) and the negative likelihood ratio was 0.26 (95% CI, 0.17-0.40). In our sensitivity analysis, when excluding participants from the validation pool who were in the original cohort, an AUC of 0.837 (95% CI, 0.748-0.926) was generated, and the AUC from the combined Montreal follow-up/PPMI/Tottori cohorts was 0.832 (95% CI, 0.761-0.903). As sex is a strong risk factor for dementia in our cohort, we divided results according to sex (maximum score = 7). Overall, performance of the scale was somewhat better in men (men: AUC, 0.916; 95% CI, 0.873-0.960; women: AUC, 0.805; 95% CI, 0.707-0.903) (eTable 5 in the Supplement).
Among de novo PPMI cohort participants, the MoPaRDS was significantly correlated with baseline values for age, Aβ 42 / Tau, and Tau protein ( Table 3) . Of the neuropsychological predictors of cognitive decline, baseline Mayo Older Americans Normative Studies-judgment of line orientation and semantic fluency were correlated with both unweighted and weighted MoPaRDS, while only the unweighted MoPaRDS correlated with verbal learning.
Discussion
In this study, we presented and validated an office-based screening tool for the risk of dementia in PD. All items independently predicted dementia development at the 5% significance level. Although different variables predicted dementia with varying strengths, weighting did not significantly improve the overall performance of the scale. Therefore, the unweighted scale can be used. At a cutoff of 4 or greater, the scale demonstrated 77.1% sensitivity and 87.2% specificity for dementia risk at 4 years. At this cutoff, a positive test result possesses a likelihood ratio of 5.94. A score of 3 or lower could be also used to "rule out" 4-year dementia risk (ie, negative predictive value = 97.6%), although a positive test result would have low specificity. Therefore, office screening for dementia risk in PD is possible.
As an office-based test, the MoPaRDS compares well with other dementia predictors that use more complex or invasive testing techniques. We found no algorithm predicting cognitive impairment that reported an AUC higher than the 0.88 observed in our study. 11 Schrag et al 10 studied the PPMI cohort, and found that a combination of lumbar puncture (CSF Aβ 42 ), DaTscan imaging (General Electric Healthcare), and clinical In this study, sensitivity for dementia prediction at 10 years was 86%, with a specificity of 72%, a diagnostic performance comparable with the MoPaRDS cutoff of 3 or greater (sensitivity, 87.1%; specificity, 68.2%) and slightly lower than the MoPaRDS cutoff of 4 or greater (sensitivity, 77.1%; specificity, 87.2%). 21 The main advantage of the MoPaRDS is its practicality for clinical use. Featuring demographic data as well as motor and nonmotor signs, the items of the scale are already often screened for in a routine office visit of a patient with PD, with no need for biological samples, neuroimaging, or genetic testing. Therefore, compiling results is rapid for the clinician during a single outpatient office visit, and the results are available without delay or requirement for statistical software. In addition to allowing prompt clinical counselling and life planning, this can have practical treatment implications. For example, drugs that can worsen cognition or induce delirium might be more assiduously avoided in those scoring in the highrisk range. Moreover, the decision about whether to use PD drugs that are more prone to causing hallucinations (eg, dopamine agonists, amantadine) will be made easier by understanding risk of developing dementia over the subsequent 4 to 5 years.
Most studies estimate that the mean time from onset of PD to dementia is 10 years, 22 and that up to 80% of patients with PD develop dementia during the disease course. 20 Therefore, predicting imminent risk may be more informative. Accordingly, the MoPaRDS was assessed for a mean (SD) of 4.4 (1.4) years and can also be used to predict annual dementia conversion rates during this time. In clinical practice, it may be most useful to divide the scale into 3 groups; low risk indicates that the development of short-term dementia is extremely unlikely (0.6% per year), high risk indicates a need for intensive surveillance (14.9% risk per year), and intermediate scores (5.8% risk per year) indicate a need for moderate surveillance and caution in using medications that are prone to cause sedation or hallucinations. Moreover, the MoPaRDS can be measured serially through time. Although some items do not change (sex) or are seen commonly in early disease (RBD, orthostatic hypotension) others, such as MCI or hallucination, more often occur late. 23 Therefore, scores should generally rise as dementia becomes imminent (note that we cannot assess this hypothesis directly using the methods of this study). The MoPaRDS may also be useful for randomized clinical trials, both for trials with dementia as an outcome and as a means to stratify patients in nondementia trials. For example, if one were to use a MoPaRDS of 4 or greater in a 3-year parallel-design clini- cal trial against PDD, an agent that reduces dementia risk by 50% would require a sample size of 69 patients (assuming 80% power with P = .05) to demonstrate a significant benefit (binominal probability, 2 proportions; https://www.stat.ubc.ca /~rollin/stats/ssize/b2.html). By contrast, without using stratification, the same clinical trial would require 568 patients, an 8-fold increase.
On the PPMI subset of the study, we found that the MoPaRDS was correlated with several biological and neuropsychological predictors of impending late-stage cognitive decline. Amyloid markers are of particular interest as dementia predictors, as Alzheimer disease pathology in patients with PD has been shown to be associated with shorter time until dementia onset. 11, 24, 25 In the Deprenyl and Tocopherol Antioxi- 
Limitations
Some limitations of this study should be noted. First, the manner of assessing MoPaRDS criteria was not exactly the same in every cohort. For example, whereas the MoPaRDS requires only clinical history of RBD, polysomnography data were available in 2 cohorts. The predictive value of polysomnogramdiagnosed RBD would be higher, perhaps increasing diagnostic performance. Also, MCI status in the Tottori cohort was only tested with the Mini-Mental State Examination at baseline, which is unreliable; therefore these values were considered missing, and 0.5 was attributed. Second, education has been variably associated with dementia risk 5, 21, 23 ; however, we did not have precise estimates of education level in 3 of 4 cohorts, so were not able to include it as a possible outcome. However, the predictive value of education is modest and not observed in all studies, so it is uncertain to what degree including education might have improved predictive value. [29] [30] [31] [32] 
Conclusions
The primary strengths of our study design are a relatively large sample size selected from diverse populations, increasing robustness and generalizability. Also, participants were monitored prospectively, reducing information bias. Our primary analysis used a "hard" outcome of dementia (rather than surrogate outcomes, such as decline in quantitative testing), an outcome that is well-defined and of obvious immediate clinical importance. Finally, the MoPaRDS itself is a short and easily administered office tool that despite its simplicity can nonetheless accurately screen for dementia risk in PD. 
